Agree Realty Highlights Thousand Oaks Biologics' Innovations at CPHI Frankfurt 2025
- Thousand Oaks Biologics showcases innovative capabilities in drug production at CPHI Frankfurt 2025, emphasizing R&D efficiency and cost reduction.
- The company offers self-sufficient raw material supply and serum-free media technology to enhance global ADC production.
- Recent upgrades to its Shanghai production site reinforce Thousand Oaks' commitment to quality and efficiency in biopharmaceutical manufacturing.
Thousand Oaks Biologics Unveils Advancements in Drug Production at CPHI Frankfurt 2025
Thousand Oaks Biologics, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in Asia, showcases its innovative capabilities at CPHI Frankfurt 2025, taking place from October 28-30. The company presents its integrated service platform at Booth 4.1H54 within the Bioproduction Zone, highlighting its role in addressing significant challenges in the biopharmaceutical industry. With a focus on improving R&D efficiency, reducing scale-up costs, and mitigating regulatory risks, Thousand Oaks positions itself as a key player in the development of antibody-drug conjugates (ADCs). These advancements are particularly relevant as China aims to globalize its innovative drug production.
A standout feature of Thousand Oaks Biologics is its self-sufficient supply of essential raw materials, bolstered by a robust quality management system that supports over 500 biopharmaceutical companies in accelerating drug development processes. The firm has pioneered serum-free media technology, which facilitates industrial-scale, self-controlled production of vital raw materials. This innovation allows for seamless scaling from laboratory trials to commercial supply, effectively meeting the growing demand for ADCs in the global market. As biopharmaceutical companies strive for faster time-to-market, Thousand Oaks Biologics’ capabilities become increasingly valuable.
In addition to its core offerings, Thousand Oaks is expanding its global reach through strategic collaborations, such as its partnership with Busan Metropolitan City in South Korea and KCell Biosciences. This collaboration aims to establish an overseas media production base, further enhancing the company's global supply network. The company’s integrated ADC Chemistry, Manufacturing, and Control (CMC) technology platform, powered by artificial intelligence, streamlines the production of naked antibodies, ADC drug substances, and drug products within a single facility. This consolidation simplifies development processes and technology transfer, reinforcing Thousand Oaks Biologics' commitment to innovation and leadership in the biopharmaceutical sector.
As the biopharmaceutical landscape continues to evolve, Thousand Oaks Biologics remains at the forefront of addressing industry challenges. The recent upgrades to its Shanghai ADC production site, which successfully passed its QP Audit in October 2025, are a testament to the company’s dedication to quality and efficiency. The facility boasts production lines capable of handling a range of scales, from 200L to 2000L for antibody drug substances and 50L to 500L for ADC conjugate drug substances. This versatility positions Thousand Oaks Biologics to meet the increasing demand for complex biologics in a competitive market.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

